Keros Therapeutics (KROS) FCF Margin (2019 - 2025)
Historic FCF Margin for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 21.86%.
- Keros Therapeutics' FCF Margin rose 79821600.0% to 21.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.3%, marking a year-over-year increase of 219251600.0%. This contributed to the annual value of 4585.92% for FY2024, which is 795015000.0% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' FCF Margin is 21.86%, which was up 79821600.0% from 167.01% recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' FCF Margin ranged from a high of 1071500.0% in Q1 2021 and a low of 431650.0% during Q3 2023
- Over the past 5 years, Keros Therapeutics' median FCF Margin value was 1521.93% (recorded in 2024), while the average stood at 33124.33%.
- In the last 5 years, Keros Therapeutics' FCF Margin crashed by 2000000000bps in 2022 and then soared by 2000000000bps in 2024.
- Over the past 5 years, Keros Therapeutics' FCF Margin (Quarter) stood at 110.19% in 2021, then soared by 92bps to 8.74% in 2022, then crashed by -207824bps to 18181.82% in 2023, then surged by 92bps to 1521.93% in 2024, then skyrocketed by 101bps to 21.86% in 2025.
- Its last three reported values are 21.86% in Q3 2025, 167.01% for Q2 2025, and 76.03% during Q1 2025.